You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Hereditary Disorders
7 September 2023 - SpliSense, an Israel-based biopharmaceutical company, announced on Wednesday that it has completed a first-in-human, Phase one clinical trial of SPL84, the company's lead inhal...
1 September 2023 - Alcresta Therapeutics, Inc., a US-based commercial-stage company involved in developing and commercialising novel enzyme-based products, announced on Thursday that the US FDA has ap...
10 August 2023 - - US-based Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from i...
13 July 2023 - Medical technology company Inogen Inc (Nasdaq:INGN) announcedon Thursday that it has entered a definitive agreement to purchase Physio-Assist SAS, a French company.Physio-Assist's ...
5 July 2023 - Biotechnology company Vertex Pharmaceuticals (NASDAQ:VRTX) announced on Wednesday that it has obtained approval from the European Commission to extend the label of ORKAMBI (lumacaftor/iv...
27 June 2023 - cystetic Medicines, Inc., a US-based clinical-stage biotechnology company, announced on Monday it has dosed its first healthy volunteer with CM001 in a Phase one clinical trial.CM001 is...
Related Headlines
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis